While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of more than 150% in the coming months. For these two stocks, CLICK HERE.